EBRO 2017

Neoadjuvant chemoradiation in esophageal cancer: CROSS trial

EBRO 2017

Median follow-up for surviving patients: 84.1 months (HR 0.68 [95% CI 0.53-0.88]; log-rank p=0.003)

SCC: HR 0.48 [95% CI 0.28-0.83]; log-rank p=0.008 AC: HR 0.73 [95% CI 0.55-0.98]; log-rank p=0.038

Shapiro et al. Lancet Oncol 2015